RecruitingNCT07039500

Impact of Severe Obstructive Sleep Apnea-Hypopnea Syndrome on Auditory-Cognitive Processing


Sponsor

Peking University First Hospital

Enrollment

100 participants

Start Date

Dec 11, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to learn how severe obstructive sleep apnea-hypopnea syndrome (OSAHS) affects the brain's ability to process sounds and attention in adults aged 20-60 years. The main questions it aims to answer are: 1. Does severe OSAHS change how the brain automatically detects sound changes during wakefulness? 2. Does severe OSAHS reduce people's ability to pay attention to important sounds when awake? 3. Can brainwave tests (Electroencephalogram, EEG) detect early signs of hearing-related cognitive problems in OSAHS patients before symptoms appear? Researchers will compare two groups: * 50 adults with severe OSAHS (diagnosed by sleep tests) * 50 healthy adults matched by age and gender Participants will: * Complete hearing tests (MoCA) * Undergo a 1-night sleep test (PSG) * Wear an EEG cap for 1.5-2 hours while listening to sounds in a quiet room: * Passive task: Relax (no response needed) * Active task: Press a button when hearing rare sounds * Receive ¥75/hour compensation for their time


Eligibility

Min Age: 20 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with auditory processing disorder and obstructive sleep apnea. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Peking University First Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07039500


Related Trials